Id: acc0393
Group: 1sens
Protein: HSP27
Gene Symbol: HSPB1
Protein Id: P04792
Protein Name: HSPB1_HUMAN
PTM: phosphorylation
Site: Ser78
Site Sequence: AAPAYSRALSRQLSSGVSEIR
Disease Category: Cancer
Disease: Colorectal Cancer
Disease Subtype:
Disease Cellline: HCT15
Disease Info:
Drug: 5-fluorouracil
Drug Info: "5-Fluorouracil (5-FU) is a pyrimidine analog antimetabolite and antineoplastic agent that inhibits thymidylate synthase, thereby interfering with DNA synthesis, and is primarily used in the treatment of colorectal, breast, gastric, pancreatic, and head and neck cancers. "
Effect: inhibit
Effect Info: Inhibit the phosphorylation of HSP27 and enhance the sensitivity of colorectal cancer cells to 5-FU.
Note:
Score: 5.0
Pubmed(PMID): 25364415
Sentence Index:
Sentence:

Sequence & Structure:

MTERRVPFSLLRGPSWDPFRDWYPHSRLFDQAFGLPRLPEEWSQWLGGSSWPGYVRPLPPAAIESPAVAAPAYSRALSRQLSSGVSEIRHTADRWRVSLDVNHFAPDELTVKTKDGVVEITGKHEERQDEHGYISRCFTRKYTLPPGVDPTQVSSSLSPEGTLTVEAPMPKLATQSNEITIPVTFESRAQLGGPEAAKSDETAAK

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 2 Unknown status squamous cell lung carcinoma ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 2 Completed pancreatic carcinoma ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 2 Completed non-small cell lung carcinoma ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 2 Completed prostate cancer ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 2 Terminated prostate cancer ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 1 Completed neoplasm ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 1 Unknown status urinary bladder cancer ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
HSPB1-Ser78
Cancer Intensity
BRCA 0.707
COAD
HGSC
ccRCC -0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 78 N Dilated cardiomyopathy Phosphorylation 34477462
S 78 P Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 22012255
S 78 U Breast cancer/tumor/carcinoma Phosphorylation 17697330
S 78 U Head and neck squamous cell carcinoma Phosphorylation 34498800

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: